Q-omics provides the consensus-scored CARTPT profile across patient tissues and cancer cell-line models. CARTPT expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CARTPT is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, CARTPT RNA expression shows 9,485 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, THCA, and GBM as cancer lineages where CARTPT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CARTPT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CARTPT survival associations across molecular data types. CARTPT RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CARTPT RNA expression–survival associations across cancer types. High CARTPT expression shows unfavorable associations in LIHC, MESO, UVM and UCEC, but favorable associations in HNSC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify HNSC as the clearest survival context for CARTPT RNA expression.
This table summarizes CARTPT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CARTPT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CARTPT shows lower tumor expression in THCA, STAD, LUAD, COAD, KICH and LUSC. The THCA box plot shows higher CARTPT RNA expression in normal versus tumor tissue (log2 FC = −6.142, t-test p < 0.001).
This table shows molecular features associated with CARTPT in patient tissues and cancer cell lines. In patient samples, CARTPT shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CARTPT RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
